Tumor Targeting in Cancer Therapy

Buch | Softcover

463 Seiten

2010 | Softcover reprint of hardcover 1st ed. 2002
Humana Press Inc. (Verlag)
978-1-61737-251-3 (ISBN)

Artikel merken

In Tumor Targeting in Cancer Therapy, Dr. Michel Page and a panel of authoritative experts from the drug industry, clinics, and academia introduce the principles and techniques of tumor targeting and critically survey their applications from laboratory to bedside. By concisely synthesizing the many technical details, the authors illuminate this innovative technique, ranging from the fundamentals of drug targeting and in vivo and in vitro experimentation, to such emerging therapeutic uses as radioimmunotherapy, radioimmunodetection, therapy with cytotoxic antibodies, immunotoxins, enzyme prodrug immunotherapy, and immunotherapeutics with fusion proteins. There are also reviews of targeting tumors with radioimmunoconjugates, photodynamic therapy, and magnetic drugs, as well as discussions of the internalization of antibodies, bioconjugation and biodistribution, the use of cytotoxic drugs, and the pros and cons of targeting by antibody or ligand.

I. A Review.- 1 The Current Status of Tumor Targeting: A Review.- 2 Clinical Applications of Targeted Therapeutics.- II. Targeting Tumors with Drug Antibody Conjugates.- 3 Targeting the CD22 Receptor with RNA Damaging Agents.- 4 The Development of Liposomes for Enhanced Delivery of Chemotherapeutics to Tumors.- 5 Overcoming Multiple Drug Resistance with Anti-Pgn Carrier.- 6 Targeting with Transferrin.- 7 Synthesis and Evaluation of Paclitaxel Immunoconjugate with Antitumor Activity In Vitro.- 8 The Use of Drug-Monoclonal Antibody Conjugates for the Treatment of Cancer.- III. Targeting Tumors with Antibodies.- 9 Targeting Vascular Endothelium with Antibodies.- 10 Targeting B-Cell Non-Hodgkin’s Lymphoma with Monoclonal Antibodies.- 11 From Bench to Bedside: Development of Rituximab (Rituxan®), A Monoclonal Antibody for the Therapy of Non-Hodgkin’s Lymphoma.- 12 Mylotarg: The First Antibody-Targeted Chemotherapy Agent..- IV. Targeting Tumors with Radioimmunoconjugates.- 13 188Rhenium-Labeled Trisuccin-?CH2HuCC49 as a Radioimmunotherapy Model in Nude Mice.- V. Targeting Tumors with Immunotoxins.- 14 General Approach for Targeting Toxins.- 15 Antibody-Toxin Conjugates: Chemistry of Coupling and Purification.- 16 Shiga-Like Toxins as Targeted Anticancer Agents.- VI. Targeting Tumors with Antibody-Enzyme Conjugates (ADEPT).- 17 Antibody-Directed Enzyme Prodrug Therapy with Carboxypeptidase G2: Clinical Studies.- VII. Photodynamic Therapy.- 18 Photodynamic Therapy: Targeting Cancer Cells with Photosensitizer-Bioconjugates.- 19 Tumor Targeting Using PEG-m-THPC for Photodynamic Therapy in a Rat Ovarian-Cancer Model.- VIII. Targeting Tumors with Magnetic Drugs.- 20 Targeting Tumors with Magnetic Drugs.- IX. Principles and Techniques in Targeting.- 21 Internalization ofAntibodies.- 22 Bioconjugation and Biodistribution.- 23 Principles of Antitumor Targeting of Cytotoxic Drugs.- 24 Targeting by Antibody or Ligand: Which Is Better?.

Erscheint lt. Verlag	19.11.2010
Reihe/Serie	Cancer Drug Discovery and Development
Zusatzinfo	39 Illustrations, black and white; X, 463 p. 39 illus.
Verlagsort	Totowa, NJ
Sprache	englisch
Maße	178 x 254 mm
Themenwelt	Medizin / Pharmazie ► Pflege
Themenwelt	Medizin / Pharmazie ► Pharmazie ► PTA / PKA
ISBN-10	1-61737-251-X / 161737251X
ISBN-13	978-1-61737-251-3 / 9781617372513
Zustand	Neuware